MGTX at a glance
MeiraGTx Holdings plc (MGTX, SEC CIK 1735438) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MeiraGTx Holdings plc (MGTX) reported revenue of $81.4 million (up 144.6% from FY2024) and a net loss of $114.2 million. Diluted EPS was -$1.42.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding MeiraGTx Holdings plc (MGTX) shares worth $230.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Forbes Alexandria on November 17, 2026 of 62,000 shares at $8.45 per share.
- In the last 90 days, MGTX insiders reported 0 open-market purchases ($0) and 3 open-market sales ($1.4M) on Form 4, a net sale of $1.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $81.4M
- +144.6% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$1.4M
- 13F holders
- 28 funds
- $230.2M · +1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $4.8M, up $0.4M YoY from $4.4M, driven by Lilly and Reogen services
- Quarterly net loss $51.3M vs $50.5M; operating loss $49.9M vs $46.1M
- Best program: AAV-hAQP1 R&D expense $6.2M, up from $2.0M; manufacturing highest at $16.7M
- Cash, cash equivalents and restricted cash $186.8M; operating cash use $45.3M through nine months
- Outlook: funding expected into second half of 2028; bota-vec EMA submission planned December 2026 and FDA BLA first quarter 2027
Risk Factors
- Newly added regulatory risk: EU pharmaceutical reforms adopted September 2026 could change data protection, exclusivity, access obligations and review procedures
- Most material financial update: Royalty Note Purchase Agreement adds up to $375 million secured obligations, with maturity on June 30, 2036
- Compliance risk: GDPR violations could trigger fines up to €20 million or 4% of worldwide annual turnover
- Near-term operational risk: Limited plasmid suppliers and manufacturing capacity could delay clinical trials or commercialization
- Liquidity risk: $186.8 million in cash, equivalents and restricted cash estimated sufficient into the second half of 2028 with assumptions- Newly added regulatory risk: EU pharmaceutical reforms adopted September 2026 could change data protection, exclusivity, access obligations and review procedures
- Most material financial update: Royalty Note Purchase Agreement adds up to $375 million secured obligations, with maturity on June 30, 2036
- Compliance risk: GDPR violations could trigger fines up to €20 million or 4% of worldwide annual turnover
- Near-term operational risk: Limited plasmid suppliers and manufacturing capacity could delay clinical trials or commercialization
- Liquidity risk: $186.8 million in cash, equivalents and restricted cash estimated sufficient into the second half of 2028 with assumptions
AI summary of the MGTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Investor focus: review the accompanying press release for revenue, cash position, expenses and pipeline updates
Item EX-99.1: Item EX-99.1
- Bota-vec MAA submission targeted December 2026, with full FDA BLA expected Q1 2027 and potential commercial launch in late 2027
- Cash, equivalents and restricted cash $186.8M, with funding projected into H2 2028 including $95.0M Hologen payment and reimbursements
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Alan M. Sebulsky appointed Class I director effective September 23, 2026, serving through the 2028 annual meeting
- Science and Technology Committee assignment adds biopharmaceutical investment and healthcare industry expertise
Item EX-99.1: Item EX-99.1
- Board appointment of Alan M. Sebulsky, a healthcare investor with over 40 years’ experience, adds biopharma capital-markets expertise
- Sebulsky previously oversaw a diversified biopharmaceutical portfolio with over $2 billion in assets at Adage Capital Management
Item 7.01: Regulation FD Disclosure
- Press release announces Alan M.’s appointment to MeiraGTx leadership
- Leadership change may affect strategic execution and investor confidence
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results cover the quarter ended June 30, 2026
- Press release issued August 13, 2026 and furnished as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $321.4M and net income $160.7M, driven largely by nonrecurring related-party license and service revenue
- R&D expense rose to $57.8M from $33.5M, reflecting bota-vec reacquisition and higher AAV2-hAQP1 clinical manufacturing and trial spending
AI summaries of MGTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MGTX
Don't miss the next MGTX filing
- Alerts as it files. A push when MGTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MGTX, by share count.
- Ask anything. An AI agent that reads every MGTX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Forbes Alexandria | Sell | Nov 17, 2026 | 62,000 | $8.45 |
| Forbes Alexandria | G | Nov 17, 2026 | 24,100 | - |
| Giroux Richard | Sell | Oct 20, 2026 | 56,000 | $9.95 |
| Naylor Stuart | Sell | Oct 6, 2026 | 27,659 | $10.64 |
| SEBULSKY ALAN | A | Sep 23, 2026 | 100,000 | - |
| Forbes Alexandria | Sell | Aug 18, 2026 | 62,000 | $13.86 |
| Giroux Richard | Sell | Jul 21, 2026 | 56,000 | $12.51 |
| Naylor Stuart | Sell | Jul 7, 2026 | 25,112 | $14.90 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $33.3M | $81.4M |
| Operating Income | - | -$164.2M | -$106.0M |
| Net Income | -$84.0M | -$147.8M | -$114.2M |
| Op. Margin | - | -493.4% | -130.2% |
| Net Margin | - | -444.1% | -140.3% |
| Balance Sheet | |||
| Total Assets | - | $269.8M | $244.4M |
| Equity | $138.2M | $67.8M | -$5.8M |
| ROE | -60.8% | -217.9% | 1971.4% |
| Per Share | |||
| EPS | $-1.49 | $-2.12 | $-1.42 |
| Cash Flow | |||
| Operating CF | - | -$104.5M | -$46.4M |
| CapEx | $20.2M | $5.0M | $3.8M |
Source: XBRL data in MeiraGTx Holdings plc (MGTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MGTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $230.2M |
| Q2 2026 | 27 | $288.2M |
| Q1 2026 | 23 | $155.5M |
| Q4 2025 | 22 | $142.1M |
| Q3 2025 | 22 | $131.7M |
| Q2 2025 | 24 | $87.4M |
| Q1 2025 | 20 | $66.6M |
| Q4 2024 | 14 | $54.9M |
- Goldman Sachs Group+819.6K (+250%)
- Invesco Ltd+114.7K (+121%)
- Vanguard Portfolio Management LLC+69.6K (+10%)
- Prudential Financial+36.8K (+131%)
- State Street Corp+32.4K (+2%)
- Citadel Advisors LLC−634.8K (-98%)
- Morgan Stanley−457.2K (-35%)
- D.E. Shaw & Co−371.4K (-44%)
- Millennium Management−238.0K (-8%)
- JPMorgan Chase & Co−166.6K (-81%)
- FMR LLC (Fidelity)−5.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MGTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 20, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 21, 2026 | - | - | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
MGTX SEC filings: frequently asked questions
Are MGTX insiders buying or selling?
In the last 90 days, MeiraGTx Holdings plc (MGTX) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $1.4 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MGTX stock?
As of September 30, 2026, the largest MeiraGTx Holdings plc (MGTX) holders among the 13F filers tracked by SignalX were Johnson & Johnson ($73.1 million), BlackRock ($51.4 million), Millennium Management ($30.1 million), State Street Corp ($15.7 million), Goldman Sachs Group ($12.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MGTX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MeiraGTx Holdings plc (MGTX) reported revenue of $81.4 million (up 144.6% from FY2024) and a net loss of $114.2 million. Diluted EPS was -$1.42. The figures come from the XBRL data in the 10-K.
What did MGTX report in its latest 8-K?
MeiraGTx Holdings plc (MGTX) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.
What are the latest MGTX SEC filings?
MeiraGTx Holdings plc (MGTX) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 17, 2026.
What is MGTX's SEC CIK number?
MeiraGTx Holdings plc (MGTX)'s SEC Central Index Key (CIK) is 1735438. EDGAR lists every MGTX filing under that number.
Ask anything about MGTX
The research agent reads MGTX's filings, financials, insider trades and 13F holders, then answers with sources.